Profil
Michael Khan is currently the Chief Executive Officer at Argonaute RNA Ltd. He is also a Member at Diabetes UK and HEART UK.
Previously, he served as the Executive Director & Chief Medical Officer at Silence Therapeutics Plc from 2013 to 2016.
He also held the position of Head-Molecular Medicine & Associate Professor at the University of Warwick.
Dr. Khan holds a doctorate degree from University College London.
Postes actifs de Michael Khan
| Sociétés | Poste | Début |
|---|---|---|
HEART UK | Corporate Officer/Principal | - |
Diabetes UK | Corporate Officer/Principal | - |
Argonaute RNA Ltd.
Argonaute RNA Ltd. Miscellaneous Commercial ServicesCommercial Services Develops safe and reliable methods of temporarily silencing target genes in different tissue cells | Directeur Général | 01/01/2021 |
Anciens postes connus de Michael Khan
| Sociétés | Poste | Fin |
|---|---|---|
| SILENCE THERAPEUTICS PLC | Directeur Technique/Scientifique/R&D | 17/06/2016 |
University of Warwick
University of Warwick Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
Formation de Michael Khan
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 6 |
|---|---|
Silence Therapeutics Plc
Silence Therapeutics Plc Miscellaneous Commercial ServicesCommercial Services Engages in the research and development of novel pharmaceutical products | Commercial Services |
University of Warwick
University of Warwick Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University College London
University College London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Diabetes UK | |
HEART UK | |
Argonaute RNA Ltd.
Argonaute RNA Ltd. Miscellaneous Commercial ServicesCommercial Services Develops safe and reliable methods of temporarily silencing target genes in different tissue cells | Commercial Services |
















